Strep Throat Treatment Market Size & Share, by Diagnosis (Antibody Test, Physical Examination, Throat Culture); End-User (Hospitals, Specialty Clinics, Diagnostic Laboratories); Treatment Type (Antibiotics, Pain Relievers); Route of Administration (Oral, Topical, Injectable); Disease Type (Acute Strep Throat, Pharyngitis, Tonsillitis, Laryngitis); Distribution Channel (Hospital Pharmacy, Retail & Online Pharmacy) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5964
  • Published Date: Apr 03, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Strep Throat Treatment Market size is expected to reach USD 3 billion by the end of 2036, growing at a CAGR of 5% during the forecast period, i.e., 2024-2036. In the year 2023, the industry of strep throat treatment was USD 2 Billion. The rise in several deaths from rheumatic heart disease mainly in industrial fields will exponentially help the strep throat treatment market to grow in the expected CAGR. Over 288 348 people die from rheumatic heart disease each year, the majority of them reside in low- or middle-income nations. Recurrent strep infections can make some people's immune systems respond negatively to bodily tissues, leading to heart valve inflammation and scarring. This is the condition known as rheumatic fever and this fever can take away lives.

Another reason to propel the strep throat treatment market by the end of 2036 is the increasing prevalence of streptococcus bacteria across the world. Some European nations (the United Kingdom, France, Ireland, the Netherlands, and Sweden) have reported a rise in invasive Group A streptococcal (iGAS) cases among children under the age of ten in 2022, especially since September. In the same time frame, reports of multiple iGAS-related deaths in children under 10 have also been made, notably from France, Ireland, and the UK. The number of pediatric iGAS cases reported in France and the UK has been several times greater than pre-pandemic values for the same time frame. The most frequent cause of bacterial pharyngitis in children of school age is GAS bacteria. Scarlet fever, a fine, red rash, and moderate symptoms such as headache, sore throat, and fever are typically the result of gas infections. The inflammation and scarring of heart valves brought on by rheumatic fever subsequently lead to rheumatic heart disease.


Slide1
Get more information on this report: Request Free Sample PDF

Strep Throat Treatment Market: Growth Drivers and Challenges

Growth Drivers

  • Increasing Global Awareness for AIDS, Flue and Ebolaviruses - Global HIV infection rates are predicted to reach 1.3 million in 2022, a 38% decrease from 2010 and a 59% decrease from the peak in 1995. In contrast to the number of persons who receive an HIV diagnosis within a year, new HIV infections, also known as "HIV incidence," refer to the estimated number of people who freshly acquired HIV during a certain period, such as a year. The resurgent Ebola virus disease (EVD) and the human immunodeficiency virus (HIV) are closely related and continue to pose a concern to public health worldwide. Their rapid spread and similar origins are accompanied by overlapping qualities that have an influence, such as linked symptoms and other interactions. Rapid response policies and evidence-based implementation results are necessary due to the global threat posed by these viruses and their disputes.
  • Rising Concern about AIDS Globally -In 2022, there were about 39 million HIV-positive individuals in the world. Of them, 1.5 million were children under the age of fifteen, and 37.5 million were adults. Furthermore, 53% of the population was female. In 2022, about 86% of HIV-positive individuals worldwide were aware of their status. About 5.5 million persons, or 14% of the population, were HIV-negative and in need of testing services. The first step in HIV prevention, treatment, care, and support services is HIV testing. 95% of people worldwide should be aware of their HIV status by 2025. The increasing use of HIV drugs\medicines is the result that people are becoming aware of aids.  
  • Increasing Government Initiatives to Reduce Streptococcus Infection Globally - Lowering the risk of a severe infection with iGAS can be achieved by reducing the transmission of GAS. Life-saving treatment for patients with iGAS illness can be started as soon as possible after the condition is identified. Therefore, public health authorities should think about initiatives to educate physicians and the general public, as well as promote early detection and treatment of GAS infections following national recommendations.

Challenges

  • Adverse Impacts Related to Strep Throat Medications - Usually, doctors recommend antibiotics to treat the strep throat bacteria, hasten your recovery, and lower your risk of developing serious consequences. Amoxicillin and penicillin are the two antibiotics that are most frequently prescribed. For people with strep throat, these medications are the primary choice because they are generally protected, moderately priced, and efficient at curing streptococcal infections in the throat. Penicillin allergies may be treated with azithromycin, cefixime, clarithromycin, or clindamycin. Unsettling stomach, yeast infections, and oral thrush (yeast overgrowth) are common antibiotic side effects.
  • Antibiotic side effects include vomiting, diarrhea, oral thrush (yeast overgrowth in the mouth), nausea, and yeast infections are common. The list of adverse effects is not exhaustive. People should talk to a healthcare provider, including your doctor, about potential side effects and drug interactions. Consuming a lot of hot liquids, like broth, soups, and hot tea. This can help you stay hydrated and relieve some of the discomfort from your sore throat.
  • Lack of Knowledge in People
  • Inclination Towards Home Remedies Over Medication

Strep Throat Treatment Market: Key Insights

Base Year

2023

Forecast Year

2036

CAGR

∼5%

Base Year Market Size (2023)

~USD 2 Billion

Forecast Year Market Size (2036)

~USD 3 Billion

Regional Scope

  • North America (North America, Canada, Mexico)
  • Europe (Germany, Spain, UK, France, Italy, Russia, Others)
  • Asia Pacific (Japan, China, India, Australia, Others)
  • Middle East and Africa (South Africa, UAE, Others)
  • Latin America (Brazil, Argentina, Others)
Get more information on this report: Request Free Sample PDF

Strep Throat Treatment Segmentation

Diagnosis (Antibody Test, Physical Examination, Throat Culture)

The antibody test segment will grow the most by the forecast period and will hold almost 58% in the strep throat treatment market because of the rising use of antibody tests to diagnose strep throat. Approximately 10 percent of school-age children regularly carry these bacteria in their upper respiratory tracts and throats without exhibiting any symptoms, and with time, they will become somewhat immune to them. Children were presumably less exposed to microorganisms at home during the COVID-19 pandemic than they were outside, so their immune systems are possibly not as powerful against these infections. Certain children are probably going to be more prone to infection in the absence of this exposure. The organism possesses several characteristics that encourage infection and enable the bacteria to penetrate, colonize, and persist in many tissues, resulting in this broad spectrum of disorders in various body areas.

Disease Type (Acute Strep Throat, Pharyngitis, Tonsillitis, Laryngitis)

The acute strep throat segment will have superior growth during the forecast period and will hold around 64% of the revenue share of the strep throat treatment market owing to the increasing cases of acute strep throat globally. Between 14,000 and 25,000 instances of invasive group A strep illness have been reported annually in the US during the last five years. Between 1,500 and 2,300 persons have lost their lives to invasive group A strep per year over the past five years. But because it's an aggressive opportunistic disease, it kills over 500,000 people globally. Close contact with an infected person can spread the infection through coughing, sneezing, or touching a wound. To mitigate or neutralize the effects of the bacterial toxin generated, intravenous fluid and electrolyte treatment is part of the supportive clinical management of severe isolated GAS infections.

Our in-depth analysis of the global strep throat treatment market includes the following segments:

     Diagnosis

  • Antibody Test
  • Physical Examination
  • Throat Culture

     End-Use Industry

  • Hospitals
  • Specialty Clinics
  • Diagnostic Laboratories

     Route of Administration

  • Oral
  • Topical
  • Injectable

     Treatment Type

  • Antibiotics
  • Pain Relievers

     Disease Type

  • Acute Strep Throat
  • Pharyngitis
  • Tonsillitis
  • Laryngitis

     Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Strep Throat Treatment Industry-Regional Synopsis

North American Market Statistics

The strep throat treatment market in the North America region will have the biggest growth during the forecast period with a revenue share of around 38%. This growth will be noticed owing to the rising advancement in technology in this region. However, Canada is fast becoming a hub for technology within North America, thus the US isn't the only place where technology innovation comes from. Our recent study of over 1,600 technology professionals confirmed the region's technological prowess, with respondents ranking North America as the world's most technologically advanced region.

European Market Analysis

The strep throat treatment market in the Europe region will also encounter huge growth during the forecast period and will hold the second position owing to the rising attainability of healthcare in this region. The Sustainable Development Goals (SDGs) objective 3.8, which calls for universal health coverage by 2030, is not likely to be achieved by the globe on track. Since 2015, progress in expanding access to health services has stalled, and since 2000, the share of the population that had to pay catastrophic amounts out of pocket for medical care has risen steadily. Most countries and all regions of the world follow this worldwide pattern.

Research Nester
Slide2
Get more information on this report: Request Free Sample PDF

Companies Dominating the Strep Throat Treatment Market

top-features-companies
    • Pfizer Inc.
      • Company Overview
      • Business Planning
      • Main Product Offerings
      • Financial Execution
      • Main Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Astrazeneca
    • Novartis AG
    • Bayer AG
    • GSK Plc.
    • Melinta Therapeutics
    • Amgen Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Merck & co, Inc.
    • Johnson & Johnson Service, Inc.
    • Takeda Pharmaceutical Company Limited
    • Sanofi
    • Mitsubishi Chemical Group Corp.
    • Daiichi Sankyo Co Ltd.

In-the-news

In The News

  • Pfizer Inc., declared that the European Commission (EC) has provided marketing authorization for the organization’s 20-valent pneumococcal conjugate vaccine, commercialized in the European Union under the brand name PREVENAR 20®, for active vaccination for the avoidance of intrusive disease, pneumonia, and severe otitis media caused by Streptococcus pneumoniae in kids, children, and adolescents from 6 weeks to lower than 18 years of age.
  • Pfizer Inc. announced top-line ABRYSVO® vaccine efficiency and protection information for a respiratory syncytial virus (RSV) in adults 60 years of age and older following a second season in the Northern and Southern Hemispheres from the continuous pivotal Phase 3 clinical trial RENOIR (RSV vaccine Efficiency study iNOlder adults Immunized against RSV disease).

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5964
  • Published Date: Apr 03, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The rise in several deaths from rheumatic heart disease mainly in industrial fields will majorly drive the market growth of the strep throat treatment market.

The market size of the strep throat treatment market is expected to get a CAGR of approximately 5% over the forecast period, i.e., 2024-2036.

The major players in the market are Pfizer Inc., Astrazeneca, Novartis AG, Bayer AG, GSK plc., Melinta Therapeutics, Amgen Inc., Teva Pharmaceutical Industries Ltd., Merck & co, Inc., Johnson & Johnson Service, Inc., Takeda Pharmaceutical Company Limited, Sanofi, Mitsubishi Chemical Group Corp., Daiichi Sankyo Co Ltd.

The antibody test segment is anticipated to reap the largest market size with almost 58% by the end of 2036 and demonstrate substantial growth scopes.

The market in the North American region is expected to have the largest market share by the end of 2036 and provide more business opportunities in the future.
Strep Throat Treatment Market Report Scope
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying